Parexel deemed most favored Phase I provider for the 4th consecutive year -- ISR Phase I CRO Quality Benchmarking Report (May 10)


"Parexel's high scores demonstrate how our collaborative approach enables us to quickly adapt, innovate and find creative solutions to overcome the industry's most pressing challenges"


About the ISR Phase I CRO Quality Benchmarking Report


Key Takeaways


Parexel recognized as Most Favored Phase I Provider for fourth consecutive year

Source: Industry Standard Research, 2021